3SOF

Applaud Rams.....
I got to get you off that 666 number  ........

Quote from: setravis on November 03, 2006, 11:20:31 AM
Applaud Rams.....
I got to get you off that 666 number  ........

I put him on 666. I thought it was most appropriate that Rams hits that milestone on this special day. 

uc.

Quote from: setravis on November 03, 2006, 11:20:31 AM
Applaud Rams.....
I got to get you off that 666 number  ........

Jesus... I thought I was the Antichrist Thanks for saving me 

Quote from: usedcasting on November 03, 2006, 12:23:55 PM

I put him on 666. I thought it was most appropriate that Rams hits that milestone on this special day.

uc.

You are evil usedcasting 

Update:
A negative reaction at $2.25, which can now be considered as a short term resistance level, GNBT has an ascending support near $2.05; we believe the stock may consolidate between these 2 levels before it breaks to the upside.

Trading Plan:
Hold with a stop @ $1.84

Best regards,

LETS SEE THAT RESISTANCE GO

Nov 06, 2006
TORONTO
MARKET WIRE 
Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that it has
entered into an agreement with the Lebanese-Canadian Hospital in Beirut, Lebanon
to conduct a human clinical trial of the Antigen Express synthetic avian
influenza vaccine, representing the first studies to be conducted in man.  The
study is being undertaken with the approval of the appropriate Lebanese
governmental and regulatory bodies.  Antigen Express, Inc., a wholly owned
subsidiary of Generex, designed the vaccine using its proprietary
platform technology and has been conducting pre-clinical studies since 2004.
Dr. Alexander Abdelnoor, Department of Microbiology & Immunology, Faculty of
Medicine, American University of Beirut, will also be participating as a
consultant for the trials.

The vaccine being developed by Antigen Express is based upon
simple peptide-synthesis technology and can thus be manufactured
rapidly, easily, and at inexpensive cost.  This is in sharp contrast
to traditional egg-based vaccines that rely on biological systems for vaccine
production, making their availability to at-risk populations during a pandemic
extremely limited.  The preclinical studies conducted with the synthetic vaccine
suggest that it may be used with more traditional vaccines to extend their
utility as well as to prevent mortality associated with H5N1 infection when used
alone.

The Antigen Express vaccine consists of specific fragments of the H5 protein
from the H5N1 influenza virus that have been modified to enhance their potency
in stimulating CD4+ T helper cells.  Flu specific T helper cells have been shown
to be essential in the development of a robust, protective immune response
against influenza.  The methods for enhancing the immune stimulating potency of
the fragments were developed by Dr. Robert Humphreys, founder of Antigen
Express.  In brief, specific fragments of the H5 protein are identified
(antigenic epitopes) that have the potential to interact with MHC class II
molecules.  The ability of CD4+ T helper cells to become stimulated to recognize
specific proteins depends upon the presentation of epitopes derived from that
protein to CD4+ cells by MHC class II molecules.  Based upon an understanding of
MHC class II charging by antigenic epitopes, Antigen Express scientists
have developed proprietary methods for increasing the vaccine potency
of antigenic peptides.

A similar synthetic peptide vaccine designed by the same methods targeting a
tumor-associated protein (encoded by HER-2/neu) has been in the clinic for more
than a year at the Walter Reed Army Medical Center (WRAMC).  That compound has
shown good activity in the antigen-specific stimulation of CD4+ T helper cells.

"The trials in Lebanon will complement nicely the studies planned for the US,"
said Dr. Eric von Hofe, President of Antigen Express.  "We know that bird flu is
a threat that shows no signs of going away soon.  Coupled with the lack of any
widely available vaccine, it is paramount to begin testing the synthetic vaccine
being developed at Antigen Express as rapidly as possible."

Up 8% in Pre-market!


Generex Biotechnology to Begin the First Human Clinical Trial of Avian Influenza Vaccine
Monday November 6, 9:10 am ET


Company Signs Agreement With the Lebanese-Canadian Hospital in Beirut as a Site for Trials


TORONTO--(MARKET WIRE)--Nov 6, 2006 -- Generex Biotechnology Corporation (NASDAQ:GNBT - News) announced today that it has entered into an agreement with the Lebanese-Canadian Hospital in Beirut, Lebanon to conduct a human clinical trial of the Antigen Express synthetic avian influenza vaccine, representing the first studies to be conducted in man. The study is being undertaken with the approval of the appropriate Lebanese governmental and regulatory bodies. Antigen Express, Inc., a wholly owned subsidiary of Generex, designed the vaccine using its proprietary platform technology and has been conducting pre-clinical studies since 2004. Dr. Alexander Abdelnoor, Department of Microbiology & Immunology, Faculty of Medicine, American University of Beirut, will also be participating as a consultant for the trials.
ADVERTISEMENT




The vaccine being developed by Antigen Express is based upon simple peptide-synthesis technology and can thus be manufactured rapidly, easily, and at inexpensive cost. This is in sharp contrast to traditional egg-based vaccines that rely on biological systems for vaccine production, making their availability to at-risk populations during a pandemic extremely limited. The preclinical studies conducted with the synthetic vaccine suggest that it may be used with more traditional vaccines to extend their utility as well as to prevent mortality associated with H5N1 infection when used alone.

The Antigen Express vaccine consists of specific fragments of the H5 protein from the H5N1 influenza virus that have been modified to enhance their potency in stimulating CD4+ T helper cells. Flu specific T helper cells have been shown to be essential in the development of a robust, protective immune response against influenza. The methods for enhancing the immune stimulating potency of the fragments were developed by Dr. Robert Humphreys, founder of Antigen Express. In brief, specific fragments of the H5 protein are identified (antigenic epitopes) that have the potential to interact with MHC class II molecules. The ability of CD4+ T helper cells to become stimulated to recognize specific proteins depends upon the presentation of epitopes derived from that protein to CD4+ cells by MHC class II molecules. Based upon an understanding of MHC class II charging by antigenic epitopes, Antigen Express scientists have developed proprietary methods for increasing the vaccine potency of antigenic peptides.

A similar synthetic peptide vaccine designed by the same methods targeting a tumor-associated protein (encoded by HER-2/neu) has been in the clinic for more than a year at the Walter Reed Army Medical Center (WRAMC). That compound has shown good activity in the antigen-specific stimulation of CD4+ T helper cells.

"The trials in Lebanon will complement nicely the studies planned for the US," said Dr. Eric von Hofe, President of Antigen Express. "We know that bird flu is a threat that shows no signs of going away soon. Coupled with the lack of any widely available vaccine, it is paramount to begin testing the synthetic vaccine being developed at Antigen Express as rapidly as possible."


http://biz.yahoo.com/iw/061106/0180295.html

A bit of a dissapointing day for GNBT as it couldn't hold on to it's gains after some good news was announced!

Quote from: AussieTrader on November 06, 2006, 09:14:26 AM
LETS SEE THAT RESISTANCE GO

Not yet Aussie... not yet 

Update:
News:
- Generex Biotechnology to Begin the First Human Clinical Trial of Avian Influenza Vaccine

Interesting news for GNBT, the stock had powerful morning rally in reaction to the news, and traded above the $2.25 area, but failed to hold those levels, and closed almost unchanged.
We'll stand with the same plan for now, and wait.

Trading Plan:
Hold with a stop @ $1.84

Best regards,

This might be another attractive entry for those on the sidelines and watching.  Ascending trendline acting as a support around 2.04, same entry price as 3SOF.  Also 10/26 to 11/2 candlesticks were Three Rising Methods, and that pattern is sometimes retested near the midpoint of the patter only to go higher IME.

Generex Biotechnology Granted New Drug Delivery Patent in Australia
Thursday November 9, 12:06 pm ET

TORONTO--(MARKET WIRE)--Nov 9, 2006 -- Generex Biotechnology Corporation (NASDAQ:GNBT - News), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has been granted a new Australian Patent by IP Australia's Patent Office titled "Pharmaceutical Compositions for Buccal and Pulmonary Application." The patent covers claims to the composition, processes, and methodologies for the delivery of macromolecules via the buccal cavity of the mouth.


The patent, an extant United States Patent held by the Company, relates to an improved pharmaceutical composition comprising macromolecule pharmaceuticals in micellar form which are particularly effective in buccal and pulmonary applications. The invention relates to methods for preparing and using these pharmaceutical compositions. Methods for enhancing the rate of absorption of a macromolecular pharmaceutical agent are also disclosed.

The Company currently holds an aggregate of 79 patents worldwide (20 of which are United States Patents) and has an aggregate of 61 patent applications pending in various jurisdictions.


http://biz.yahoo.com/iw/061109/0182453.html

Update:
GNBT has been performing poorly, testing the support level, and closing slightly below it last Friday.
Essentially we need a quick reaction to the upside, in order to hold this position; we'll keep it but we need to upgrade our stop at this point, since $1.84 is no longer adequate after this chart development, so the new trading plan is:

Trading Plan:
Hold with a stop @ $1.95

Best regards,

Update:
Great development for GNBT (and all bird full plays), the stock is now trading again above its ascending support, and the chart is once again showing a lot of strength. $2.25 is the short term barrier, but we expect this to be surpassed quickly. We'll stand with the same plan for now:

Trading Plan:
Hold with a stop @ $1.95

Best regards,

Update:
Nice session Not a big price advance, but an important close above the$2.25 resistance level. We'll keep this trading plan intact, even if we should start thinking about increasing our stop level.

Trading Plan:
Hold with a stop @ $1.95

Best regards,

Update:
Once again, GNBT had a bad reaction near the $2.25 reactive level, we have made a small change on the chart's TA, and now we are considering an ascending triangle pattern for the short term. GNBT closed neat the ascending bottom of the pattern so lets just wait... For upside purposes we need that $2.25 breakout to trigger a new consistent rally.
Our plan fits this new TA approach, so it will be the same:

Trading Plan:
Hold with a stop @ $1.95

Best regards,

Update:
GNBT had a positive reaction on the triangle's ascending support, volume was low, and there were no special events to report.
We'll just stand with the same plan:

Trading Plan:
Hold with a stop @ $1.95

Best regards,